as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹21,102.0
Change
-353.0 (-1.65%)
Open
₹21,400.0
Prev. Close
₹21,455.0
Day High
₹21,535.0
Day Low
₹21,019.0
Volume Analysis
Traded
34,815
Delivered
18,232
Delivery %
52.37%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (21.2%)
- •Strong operating margin (31.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (30.6%)
- •Strong 3-year revenue growth (19.3%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹21,934.34 | ₹21,734.67 | ₹21,418.34 | ₹21,218.67 | ₹20,902.34 | ₹20,702.67 | ₹20,386.34 |
| Fibonacci | ₹21,734.67 | ₹21,537.56 | ₹21,415.78 | ₹21,218.67 | ₹21,021.56 | ₹20,899.78 | ₹20,702.67 |
| Camarilla | ₹21,243.9 | ₹21,196.6 | ₹21,149.3 | ₹21,218.67 | ₹21,054.7 | ₹21,007.4 | ₹20,960.1 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+40.12%
1 Week
+0.86%
1 Month
+11.21%
3 Months
-9.44%
6 Months
+26.41%
1 Year
+26.22%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹3,177.84
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.61%
Net margin 19.64% × asset turnover 0.67x × equity multiplier 1.49x
Company Overview
Sector
Healthcare
Market Cap
₹27,106 Cr
P/E (TTM)
59.9
ROE
21.2%
Book Value
₹1,582.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Neuland Lab Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (21.2%); strong operating margin (31.0%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
68/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 38.5% CAGR over last 5 years
- −Stock is trading at 13.4 times its book value
- −Promoter holding has decreased over last quarter: -0.36%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of the Earnings Call conducted on November 3, 2026
Management to attend JM Financial Annual India Conference in Mumbai on November 17, 2026.
KFin Technologies’ corporate office shifts to Kokapet, Hyderabad from December 1, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 | 450 |
| Expenses + | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 | 352 |
| Operating Profit | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 | 98 |
| OPM % | 33.0% | 31.0% | 28.0% | 28.0% | 20.0% | 22.0% | 16.0% | 12.0% | 30.0% | 18.0% | 40.0% | 35.0% | 22.0% |
| Other Income + | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 | 8 |
| Interest | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 | 7 |
| Depreciation | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 | 29 |
| Profit before tax | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 | 69 |
| Tax % | 27.0% | 22.0% | 27.0% | 25.0% | 34.0% | 20.0% | 29.0% | 21.0% | 25.0% | 26.0% | 26.0% | 25.0% | 25.0% |
| Net Profit + | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 | 52 |
| EPS in Rs | 70 | 63 | 53 | 76 | 26 | 79 | 22 | 11 | 75 | 32 | 166 | 115 | 40 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 42 | 46 | -5 | 21 | -26 | 1 | -15 | -33 | 65 | 10 | 136 | 119 | -13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 | 2,307 |
| Expenses + | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,096 | 1,146 | 1,443 | 1,602 |
| Operating Profit | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 580 | 705 |
| OPM % | 14.0% | 16.0% | 18.0% | 10.0% | 9.0% | 13.0% | 16.0% | 15.0% | 23.0% | 30.0% | 22.0% | 29.0% | 31.0% |
| Other Income + | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 90 | 25 | 36 |
| Interest | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 14 | 8 | 24 | 28 |
| Depreciation | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 92 | 104 |
| Profit before tax | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 489 | 609 |
| Tax % | 36.0% | 36.0% | 30.0% | 13.0% | 19.0% | 69.0% | 23.0% | 22.0% | 24.0% | 25.0% | 25.0% | 26.0% | — |
| Net Profit + | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 364 | 453 |
| EPS in Rs | 18 | 31 | 53 | 14 | 13 | 13 | 63 | 50 | 127 | 234 | 203 | 284 | 353 |
| Dividend Payout % | 8.0% | 7.0% | 0.0% | 0.0% | 0.0% | 16.0% | 8.0% | 10.0% | 8.0% | 6.0% | 6.0% | 12.0% | — |
| Sales growth | 1 | 9 | 14 | -9 | 26 | 14 | 23 | 2 | 25 | 31 | -5 | 37 | 50 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 | 1,862 | 2,017 |
| Borrowings + | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 | 301 | 342 |
| Other Liabilities + | 162 | 155 | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 454 | 498 | 754 | 658 |
| Total Liabilities | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,930 | 3,030 |
| Fixed Assets + | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 | 1,177 | 1,278 |
| CWIP | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 48 | 211 | 284 |
| Investments | 7 | 7 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 | 2 | 2 |
| Other Assets + | 340 | 337 | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 962 | 1,068 | 1,541 | 1,465 |
| Total Assets | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,930 | 3,030 |
| Equity Capital | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | 261 | 317 | 347 |
| Cash from Investing Activity + | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -95 | -61 | -150 | -298 | -423 |
| Cash from Financing Activity + | 1 | -24 | 0 | 105 | 12 | -5 | -114 | 38 | -136 | -69 | 25 | 21 |
| Net Cash Flow | 0 | 1 | -4 | 0 | 5 | 3 | -9 | 3 | 40 | 42 | 44 | -55 |
| Free Cash Flow | -1 | 26 | -2 | -121 | 7 | 9 | 84 | -37 | 173 | 119 | 112 | -50 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 33 | 70 | 52 | 28 | 128 | 61 | 132 | 56 | 103 | 81 | 119 | 78 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 38.1% | 35.88% | 34.77% | 34.12% | 33.96% | 33.85% | 33.67% | 32.8% | 31.76% | 31.08% | 29.79% | 29.55% |
| Promoters | 32.8% | 32.74% | 32.72% | 32.64% | 32.68% | 32.67% | 32.67% | 32.64% | 32.63% | 32.63% | 32.62% | 32.26% |
| Government | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| FII | 22.69% | 24.43% | 25.72% | 26.46% | 23.86% | 22.12% | 21.69% | 20.6% | 20.9% | 20.46% | 21.08% | 21.93% |
| DII | 6.02% | 6.54% | 6.39% | 6.38% | 9.09% | 10.97% | 11.57% | 13.55% | 14.72% | 15.84% | 16.52% | 16.25% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Neuland Lab Ltd. (this stock) | 27,106 | 59.9 | 13.35 | 21.2% |
| Rubicon Research Limited | 27,764 | 85.5 | 19.59 | 27.0% |
| Krishna Inst Of Med Sci L | 31,903 | 157.0 | 8.11 | 11.3% |
| Granules India Limited | 22,226 | 31.7 | 3.39 | 13.8% |
| Acutaas Chemicals Limited | 32,281 | 73.5 | 17.37 | 24.0% |
| Piramal Pharma Limited | 32,557 | — | 4.0 | -3.83% |
| Wockhardt Limited | 32,944 | 82.4 | 6.39 | 6.11% |
Which Mutual Funds Hold Neuland Lab Ltd.?
Frequently Asked Questions about Neuland Lab Ltd.
Neuland Lab Ltd. (NEULANDLAB) closed at ₹21,102.0 on NSE on 19 November 2026, down 353.0 (1.65%) from the previous close.
Neuland Lab Ltd. trades on the NSE (National Stock Exchange of India) under the symbol NEULANDLAB.
Neuland Lab Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 59.9.
Neuland Lab Ltd. has a dividend yield of 0.16%.
Neuland Lab Ltd.'s 52-week high is ₹24,235.0 and its 52-week low is ₹11,500.0.
Neuland Lab Ltd. has a market capitalisation of ₹27,106 crore.
Neuland Lab Ltd. has a TopFund Quality Score of 68/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Neuland Lab Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.